The pharmaceutical* equipment manufacturing industry welcomes heavy benefits and will accelerate innovation and upgrading

[ Chemical Machinery Equipment Network Market Analysis ] It is reported that on January 1, 2021, the rate of deduction for R&D expenses of manufacturing enterprises will increase from 75% to 100%.
Under the implementation of this policy, it means that for every 1 million yuan invested in research and development expenses, 2 million yuan can be deducted from the taxable income, which greatly benefits the innovation and development of manufacturing enterprises.

China's manufacturing industry is mainly divided into instrument and meter manufacturing, general equipment manufacturing, * equipment manufacturing, electrical machinery and equipment manufacturing, metal products, machinery and equipment repairing, chemical raw materials and chemical products manufacturing, pharmaceutical manufacturing, rubber And plastic products industry, metal products industry and other major categories.

 

According to the "National Economic Industry Classification and Code (GB/T4754-2017)" formulated by the country*, pharmaceutical equipment manufacturing is also included in the equipment manufacturing industry, which refers to the production of chemical raw materials and pharmaceuticals, Chinese herbal medicines and proprietary Chinese medicines* The manufacture of the equipment, its level 4 code is C3544.
With the implementation of the above-mentioned tax reduction policy, the pharmaceutical equipment manufacturing industry will also usher in heavy benefits, which will further encourage the pharmaceutical equipment manufacturing industry to continue to innovate and accelerate industrial upgrading.

 

Pharmaceutical* equipment can be divided into eight categories, including API machinery and equipment, preparation machinery and equipment, medicinal crushing machinery, decoction pieces machinery, pharmaceutical water treatment equipment, pharmaceutical packaging machinery, drug testing equipment, other pharmaceutical machinery and equipment parts Wait.
As the upstream of the pharmaceutical industry, with the rapid development of the pharmaceutical industry in recent years, the number of enterprises above designated size in my country's pharmaceutical* equipment has continued to increase, and the scale of the industry has also continued to expand.

 

According to national* data, at the end of 2019, there were 124 enterprises above designated size in my country's pharmaceutical equipment manufacturing industry, with total industry assets of 26.
204 billion yuan and a total output value of 19.
308 billion yuan.
In 2019, the sales revenue of my country's pharmaceutical equipment manufacturing industry was 17.
270 billion yuan.

 

　　From the perspective of the development of the industry, my country’s pharmaceutical* equipment has gradually moved from the imitation stage at the beginning to the stage of imitation and innovation and independent innovation.
Technology continues to advance.
Today, the pharmaceutical machinery market has a complete range of product specifications and a wide range of products, which can basically meet the requirements of the domestic market.
The needs of pharmaceutical companies.

 

　　At the same time, more and more domestic enterprises are also pushing their products to overseas markets, and industry exports have increased.
According to CEIC statistics, the export delivery value of my country's pharmaceutical* equipment in 2019 was 1.
696 billion yuan, but it was down from 2.
011 billion yuan in 2018.

 

　　In addition, from the perspective of the competitive landscape of the industry, facing the huge growth space of my country's pharmaceutical market, foreign pharmaceutical giants have paid more attention to the scale of investment and sales in the Chinese market in recent years, relying on their advantages in capital, technology, R&D, and talents.
Won the main market share of domestic* pharmaceutical equipment.
However, domestic pharmaceutical machinery companies are mainly small and medium-sized, lack of overall R&D investment, weak innovation strength, and lack of production capacity for some high-tech equipment, making it difficult to create high value-added products with independent intellectual property rights.
Moreover, the industry concentration is relatively low, and competition is mainly low-end pharmaceutical equipment.
Compared with foreign pharmaceutical equipment, domestically produced traditional Chinese medicine equipment still has a large gap.

 

　　In general, there is huge room for domestically-made pharmaceutical* equipment to replace imports.
With the normalization of centralized drug procurement, it is expected that more pharmaceutical companies will accelerate the upgrading of equipment, and the pharmaceutical machinery industry can still benefit from the rapid growth brought by upstream in the next few years.
In this context, domestic pharmaceutical companies need to continue to focus on the * field, and the promotion of tax reduction policies will help boost the innovation of domestic pharmaceutical companies and help the entire industry to innovate and upgrade.

 

　　Original title: The pharmaceutical* equipment manufacturing industry welcomes heavy benefits and will accelerate innovation and upgrading